Royalty Conditions. The royalties under Section 8.3.1 shall be subject to the following conditions: a) that only one royalty shall be due with respect to the same unit of Licensed Product; b) that no royalties shall be due upon the sale or other transfer among Retrophin, its Affiliates, or Sublicensees, but in such cases the royalty shall be due and calculated upon Retrophin’s or its Affiliate’s or Sublicensee’s Net Sales of Licensed Product to the first independent Third Party; and c) no royalties shall accrue on the disposition of Licensed Product in reasonable quantities by Retrophin, its Affiliates or Sublicensees as part of an expanded access program, as bona fide samples, as part of Phase 4 Trials or as donations to non-profit institutions or government agencies for non-commercial purposes; provided, however, in each case, that neither Retrophin, its Affiliate or Sublicensees receives any payment for such Licensed Product.
Appears in 4 contracts
Samples: Sublicense Agreement (Ligand Pharmaceuticals Inc), Sublicense Agreement (Ligand Pharmaceuticals Inc), Sublicense Agreement (Desert Gateway, Inc.)